JP2023513188A5 - - Google Patents

Info

Publication number
JP2023513188A5
JP2023513188A5 JP2022547885A JP2022547885A JP2023513188A5 JP 2023513188 A5 JP2023513188 A5 JP 2023513188A5 JP 2022547885 A JP2022547885 A JP 2022547885A JP 2022547885 A JP2022547885 A JP 2022547885A JP 2023513188 A5 JP2023513188 A5 JP 2023513188A5
Authority
JP
Japan
Prior art keywords
seq
gene
protein
subject
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/050974 external-priority patent/WO2021156831A1/en
Publication of JP2023513188A publication Critical patent/JP2023513188A/ja
Publication of JP2023513188A5 publication Critical patent/JP2023513188A5/ja
Pending legal-status Critical Current

Links

JP2022547885A 2020-02-07 2021-02-05 遺伝子の発現増加のためのmirna-485阻害剤 Pending JP2023513188A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062971767P 2020-02-07 2020-02-07
US62/971,767 2020-02-07
US202062989486P 2020-03-13 2020-03-13
US62/989,486 2020-03-13
US202063047155P 2020-07-01 2020-07-01
US63/047,155 2020-07-01
US202063064314P 2020-08-11 2020-08-11
US63/064,314 2020-08-11
PCT/IB2021/050974 WO2021156831A1 (en) 2020-02-07 2021-02-05 Mirna-485 inhibitor for gene upregulation

Publications (2)

Publication Number Publication Date
JP2023513188A JP2023513188A (ja) 2023-03-30
JP2023513188A5 true JP2023513188A5 (cg-RX-API-DMAC7.html) 2024-02-14

Family

ID=77200819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547885A Pending JP2023513188A (ja) 2020-02-07 2021-02-05 遺伝子の発現増加のためのmirna-485阻害剤

Country Status (9)

Country Link
US (1) US20230126157A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100067A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023513188A (cg-RX-API-DMAC7.html)
KR (1) KR20220154104A (cg-RX-API-DMAC7.html)
CN (1) CN115443154A (cg-RX-API-DMAC7.html)
AU (1) AU2021216720A1 (cg-RX-API-DMAC7.html)
CA (1) CA3166709A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009448A (cg-RX-API-DMAC7.html)
WO (1) WO2021156831A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024228119A1 (en) * 2023-05-01 2024-11-07 Biorchestra Co., Ltd. Mirna-485 inhibitors
WO2024228118A1 (en) * 2023-05-01 2024-11-07 Biorchestra Co., Ltd. Mirna-485 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951330B2 (en) * 2013-07-11 2018-04-24 The Trustees Of Columbia University In The City Of New York Micrornas that silence tau expression
DK3378482T5 (da) * 2015-11-19 2024-09-30 Univ Nagoya City Public Univ Corp Formulering til administration af antitumorlægemiddel
RU2016146594A (ru) * 2016-11-28 2018-05-28 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" Средство для лечения деменции различной этиологии
WO2018139819A1 (ko) * 2017-01-26 2018-08-02 주식회사 바이오오케스트라 마이크로 rna를 이용한 뇌 질환 예방 또는 치료 용도
CN107287319B (zh) * 2017-07-13 2021-07-02 青岛大学 miRNA-485-5p核苷酸类似物及其反义核苷酸的应用和应用其的产品
WO2019240223A1 (ja) * 2018-06-13 2019-12-19 公益財団法人川崎市産業振興財団 数平均分子量が3kDa~10kDaであるPEGブロックとカチオン性ポリマーとのブロックコポリマーと、アンチセンスオリゴヌクレオチドとを含む、ポリイオンコンプレックスミセル
KR20220024160A (ko) * 2019-06-17 2022-03-03 주식회사 바이오오케스트라 마이크로rna를 이용하여 알츠하이머 질환 동물 모델을 준비하기 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2022538868A5 (cg-RX-API-DMAC7.html)
Yang et al. Efficient cytosolic delivery of siRNA using HDL‐mimicking nanoparticles
EP3411059B1 (en) Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
Liu et al. Investigation of the performance of PEG–PEI/ROCK-II-siRNA complexes for Alzheimer's disease in vitro
US10113151B2 (en) Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
Rodriguez-Gascon et al. Vaginal gene therapy
Reimondez-Troitiño et al. Versatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells
JP2023532536A5 (cg-RX-API-DMAC7.html)
Fraga et al. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model
Sarisozen et al. Lipid-based siRNA delivery systems: challenges, promises and solutions along the long journey
JP2023513190A5 (cg-RX-API-DMAC7.html)
Botto et al. Cationic solid lipid nanoparticles as non viral vectors for the inhibition of hepatocellular carcinoma growth by RNA interference
Sasaki et al. Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy
Ouyang et al. A biomimic reconstituted high-density-lipoprotein-based drug and p53 gene co-delivery system for effective antiangiogenesis therapy of bladder cancer
Oryan et al. Basic concepts, current evidence, and future potential for gene therapy in managing cutaneous wounds
JP2024501437A5 (cg-RX-API-DMAC7.html)
JP2023513189A5 (cg-RX-API-DMAC7.html)
Malfanti et al. Control of cell penetration enhancer shielding and endosomal escape-kinetics crucial for efficient and biocompatible siRNA delivery
IL316806A (en) Compositions and methods for treating monogenic neurodevelopmental disorder
Baradaran et al. A novel method for the development of plasmid DNA-loaded nanoliposomes for cancer gene therapy
US20260048147A1 (en) Aav capsid proteins having mutations in the vp1 region
Tahara et al. A novel double-coating carrier produced by solid-in-oil and solid-in-water nanodispersion technology for delivery of genes and proteins into cells
US12582669B2 (en) Composition controlling pharmacokinetics in the body
JP2024503302A5 (cg-RX-API-DMAC7.html)
JP2024503303A5 (cg-RX-API-DMAC7.html)